Nventa announces publication of HspE7 data

    - HspE7 Demonstrates Ability to Elicit Long-Lasting Tumor Protection In
    Vivo; Lead Candidate May Have Utility in HPV-infected Patients With
    Invasive Cancer and/or HIV -

    SAN DIEGO, CA, Sept. 24 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) today announced the publication of in vivo results of its lead
therapeutic vaccine candidate for the treatment of human papillomavirus
(HPV)-related diseases, HspE7, in Clinical and Vaccine Immunology, August
2007. The results reported originate from a study undertaken to characterize
the cellular anti-E7 immune response induced by HspE7 and to determine the
optimum dosing regimen for inducing effective antitumor immunity.
    These published study results demonstrated that a single injection of
HspE7 is capable of eliciting long-lasting memory CD8+ T cells and conferring
protection against tumor challenges in mice lacking CD4+ functions. CD8+ T
cells are a type of white blood cell capable of inducing the death of infected
somatic or tumor cells by killing cells infected with viruses (or other
pathogens) or otherwise damaged or dysfunctional. These data further
demonstrated that two HspE7 immunizations protected a higher proportion of
mice for a longer duration.
    "These results further strengthen our belief that HspE7 is a promising
immunotherapeutic agent for treating HPV-related diseases," said Peter Emtage,
Ph.D., Vice President, Research and Development at Nventa. "The ability of
HspE7 to induce memory CD8+ T cells in the absence of CD4+ help is significant
and suggests that our HspE7 fusion protein may have utility in individuals
with compromised CD4+ functions, such as those with invasive cancer and/or
human immunodeficiency virus infection."
    HPV has been detected in most anogenital cancers, and HPV type 16 (HPV16)
is closely associated with severe cervical dysplasia and with cervical, anal
and approximately 25 percent of head and neck cancers. Evidence indicates that
proper immunosurveillance can impede the development of HPV-associated tumors
and that T-cell immunity is important in the resolution and control of
HPV-induced diseases.

    About HspE7, Lead Product Candidate:
    HspE7 is a novel therapeutic vaccine candidate for the treatment of
diseases caused by the human papillomavirus (HPV), one of the most common
sexually transmitted diseases in the world. HspE7 is derived from Nventa's
proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology
to covalently fuse stress proteins to target antigens, thereby stimulating
cellular immune system responses. Heat shock proteins (Hsps), also known as
stress proteins, are naturally present in the human body and play important
roles in the immune system, including transporting substances within cells and
activating cells of the immune system. Nventa is pursuing clinical development
of new HspE7 (HspE7 dosed with an adjuvant).

    About Nventa Corporation:
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa, please visit

    This press release contains statements which, to the extent that they are
not recitations of historical fact may constitute forward-looking information
under applicable Canadian securities legislation or forward-looking statements
within the meaning of the United States Private Securities Litigation Reform
Act of 1995. Such forward-looking statements or information may include
financial and other projections as well as statements regarding the Company's
future plans, objectives, performance, revenues, growth, profits, operating
expenses or the Company's underlying assumptions. The words "may", "would",
"could", "will", "likely", "expect," "anticipate," "intend", "plan",
"forecast", "project", "estimate" and "believe" or other similar words and
phrases are intended to identify forward-looking statements or information.
Persons reading this press release are cautioned that such statements or
information are only predictions, and that the Company's actual future results
or performance may be materially different.
    Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning: our HspE7 fusion
protein's potential utility in individuals with compromised CD4+ functions.
    Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially different from
any future results, events or developments expressed or implied by such
forward-looking statements or information. Such factors include, among others,
our need for capital, risks associated with requirements for approvals by
government agencies such as the FDA before products can be tested in clinical
trials; the possibility that such government agency approvals will not be
obtained in a timely manner or at all or will be conditioned in a manner that
would impair our ability to advance development; risks associated with the
requirement that a drug be found safe and effective after extensive clinical
trials and the possibility that the results of such trials, if commenced and
completed, will not establish the safety or efficacy of our products; our
dependence on suppliers, collaborative partners and other third parties and
the prospects and timing for negotiating supply agreements, corporate
collaborations or licensing arrangements; our ability to attract and retain
key personnel; our ability to protect and practice our intellectual property;
and other factors as described in detail in our filings with the Canadian
securities regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement.
    Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that we will raise enough capital, on reasonable terms and in a timely
manner; that we will retain our key personnel; that we will obtain the
necessary regulatory approvals related to HspE7 and our adjuvant in a timely
manner; that enough HspE7 will be available to conduct our planned trials;
that we will be able to procure the necessary amount of adjuvant to conduct
our planned trials; that we will obtain timely approval from IRB; that the
results from additional preclinical and clinical work, if any, will be
consistent with the results we have already obtained; that a sufficient number
of patients will be available to conduct our planned trials; and that
sufficient data will be generated to support an IND.
    In the event that any of these assumptions prove to be incorrect, or in
the event that we are impacted by any of the risks identified above, we may
not be able to continue in our business as planned.
    For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, including our 2006 Annual
Information Form filed on SEDAR at http://www.sedar.com. Historical filings
relating to the Company prior to the completion of the Company's March 23,
2006 corporate reorganization, including Old Stressgen's 2005 Annual
Information Form dated March 16, 2006 may be reviewed on SEDAR at
http://www.sedar.com under the SEDAR profile GVIC Publications Ltd.
    All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
by law.

    %SEDAR: 00023483E

For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, San Diego, CA, USA 92121, Dir: (858) 202-4945,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890